华康生物医学(08622)发布中期业绩，净亏损236.9万元，同比扩大33.2%

Group 1 - The core viewpoint of the article highlights Huakang Biomedical's financial performance for the six months ending June 30, 2025, showing a revenue of 12.329 million RMB, which represents a year-on-year increase of 3.4% [1] - The company reported a net loss of 2.369 million RMB, which is an increase of 33.2% compared to the previous year [1] - The basic loss per share is reported at 0.47 cents [1] Group 2 - The increase in revenue is attributed to higher sales of male infertility in vitro diagnostic reagents and a series of parasitic testing reagents during the reporting period [1]